Impact of Doxycycline as Malaria Prophylaxis on Risk of Influenza-Like Illness among International Travelers.
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
12
2
2020
medline:
24
6
2020
entrez:
12
2
2020
Statut:
ppublish
Résumé
Travelers are often at risk for both influenza-like illness (ILI) and malaria. Doxycycline is active against pathogens causing ILI and is used for malaria prophylaxis. We evaluated the risk factors for ILI, and whether the choice of malaria prophylaxis was associated with ILI. TravMil is a prospective observational study enrolling subjects presenting to military travel clinics. Influenza-like illness was defined as subjective fever with either a sore throat or cough. Characteristics of trip and use of malaria prophylaxis were analyzed to determine association with development of ILI. Poisson regression models with robust error variance were used to estimate relative risk (RR) of ILI. A total of 3,227 trips were enrolled: 62.1% male, median age of 39 years (interquartile range [IQR] 27,59), median travel duration 19 days (IQR 12, 49); 32% traveled to Africa, 40% to Asia, and 27% to the Caribbean and Latin America. Military travel (46%) and vacation (40%) were most common reasons for travel. Among them, 20% took doxycycline, 50% other prophylaxis, and 30% took none; 8.7% developed ILI. Decreased RR of ILI was associated with doxycycline (RR 0.65 [0.43-0.99],
Identifiants
pubmed: 32043448
doi: 10.4269/ajtmh.19-0648
pmc: PMC7124920
doi:
Substances chimiques
Antimalarials
0
Doxycycline
N12000U13O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-826Références
Am J Trop Med Hyg. 2018 Nov;99(5):1269-1274
pubmed: 30226131
Travel Med Infect Dis. 2016 Jul-Aug;14(4):389-97
pubmed: 27320130
J Antimicrob Chemother. 2003 Aug;52(2):229-46
pubmed: 12865398
N Engl J Med. 2017 Feb 9;376(6):548-560
pubmed: 28177860
Proteomics. 2011 Jan;11(1):42-51
pubmed: 21182193
Thorax. 2007 Jan;62 Suppl 1:1-46
pubmed: 17202446
PLoS One. 2009 Jul 01;4(7):e6118
pubmed: 19568433
Cochrane Database Syst Rev. 2013 Nov 28;(11):CD009764
pubmed: 24288145
Mini Rev Med Chem. 2012 Jan;12(1):44-52
pubmed: 22070692
Clin Infect Dis. 2003 Feb 15;36(4):399-406
pubmed: 12567296
Vaccine. 2000 Jul 1;18(26):2956-62
pubmed: 10825596
J Clin Virol. 2013 May;57(1):54-8
pubmed: 23380660
PLoS One. 2014 Jan 08;9(1):e85094
pubmed: 24416345
PLoS One. 2009 Jul 08;4(7):e6177
pubmed: 19584919
Am J Prev Med. 2011 Dec;41(6):573-80
pubmed: 22099233
Ann Intern Med. 2013 Mar 19;158(6):456-68
pubmed: 23552375
Thorax. 2011 May;66(5):389-95
pubmed: 21357586
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
J Travel Med. 2017 Jan 11;24(1):
pubmed: 28077609
Mediators Inflamm. 2015;2015:329418
pubmed: 25977597